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Abstract
Background: Adult rats exposed to methylazoxymethanol (MAM) at embryonic day 17 (E17) consistently display behavioral
characteristics similar to that observed in patients with schizophrenia and replicate neuropathological findings from the
prefrontal cortex of psychotic individuals. However, a systematic neuropathological analysis of the hippocampal formation
and the thalamus in these rats is lacking. It is also unclear if reelin, a protein consistently associated with schizophrenia and
potentially involved in the mechanism of action of MAM, participates in the neuropathological effects of this compound.
Therefore, a thorough assessment including cytoarchitectural and neuromorphometric measurements of eleven brain
regions was conducted. Numbers of reelin positive cells and reelin expression and methylation levels were also studied.
Principal Findings: Compared to untreated rats, MAM-exposed animals showed a reduction in the volume of entorhinal
cortex, hippocampus and mediodorsal thalamus associated with decreased neuronal soma. The entorhinal cortex also
showed laminar disorganization and neuronal clusters. Reelin methylation in the hippocampus was decreased whereas
reelin positive neurons and reelin expression were unchanged.
Conclusions: Our results indicate that E17-MAM exposure reproduces findings from the hippocampal formation and the
mediodorsal thalamus of patients with schizophrenia while providing little support for reelin’s involvement. Moreover, these
results strongly suggest MAM-treated animals have a diminished neuropil, which likely arises from abnormal neurite
formation; this supports a recently proposed pathophysiological hypothesis for schizophrenia.
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Introduction
Accumulating evidence suggests that schizophrenia originates
from abnormal central nervous system (CNS) development [1,2].
Data supporting this premise come in particular from cytoarchi-
tectural studies of patients in whom heterotopias, laminar
disorganization and neuronal clusters in the hippocampal
formation have been reported [3–7]. Although these findings
have not been always replicated [8–10], other anatomical and
neuromorphometric changes in affected individuals are more
consistent. Among such deficiencies are a smaller hippocampus
and entorhinal cortex, both of which are associated with reduced
neuronal body sizes [11–19]. Neuropathological and electrophys-
iological studies support GABAergic interneurons as a key actor in
the pathophysiology of schizophrenia [20,21]. In the prefrontal
cortex (PFC) and in the hippocampus these neurons express reelin
[22] and previous studies have consistently found reelin’s
expression to be decreased in the PFC, hippocampus, caudate
nuclei and cerebellum of patients with this psychotic illness
[23,24]. Other common findings include a decreased number of
reelin-containing cells in the PFC, cerebellum and hippocampus
[23–25] as well as hypermethylation of the reelin promoter [26–
28], although the most recent study did not replicate this latter
finding [29].
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schizophrenia [1,2], exposure to Methylazoxymethanol acetate
(MAM) during rats’ embryonic life has been used to model this
psychotic illness. Several embryonic days have been tested,
ranging from embryonic days (ED) 9 to 12 [30–32] and most
recently embryonic day 17 [33–35]. MAM, an anti-mitotic
alkylating agent [36], is injected into pregnant rats to disrupt the
pups’ CNS development. This compound induces programmed
cell death in neuroepithelial proliferating cells [37] without causing
any teratogenic effects in any other organs [38]. Embryonic day 17
(E17) was selected because it is when neurogenesis peaks in the
hippocampal formation [39] and when projections from the
hippocampus to the entorhinal cortex are established in rats [40].
Since the hippocampal formation is considered central for the
pathology of schizophrenia [41], disrupting this brain region’s
development seems crucial to model such an illness. MAM
exposure earlier in embryonic development also affects the
hippocampal formation [30–32] but it is adult rats exposed to
MAM at E17 which display behaviors that resemble some
characteristics observed in schizophrenia such as social withdrawal
[42,43], hypersensitivity to amphetamines and NMDA-antagonists
[42–44], sensory gating anomalies [43,45] and cognitive impair-
ments [35,42,43,46]. Less information, however, is currently
available regarding possible neuropathological anomalies present
in these animals.
Three independent groups have reported cortical and hippo-
campal size reductions in MAM E17 rats [35,42,47]. More
recently, the MAM E17 model was found to reproduce whole
neuronal density changes from the PFC and parvalbumin-positive-
cell density deficits from the hippocampus and the PFC of patients
with schizophrenia [45,48]. Along with these findings, a smaller
mediodorsal thalamic nucleus and a smaller hippocampus were
described [45] but further analysis of these brain regions involving
neuronal density, size, morphology and localization were not
pursued. Consequently, the first goal of our work was to determine
the neuropathological substrate of the hippocampal formation and
thalamus size reductions in the MAM model and to establish if
such a neuropathological substrate correlates with deficiencies
observed in patients with schizophrenia. In order to achieve this
goal, we conducted a thorough examination of the hippocampus
(HIP), dentate gyrus (DG), entorhinal (ERC) and perirhinal
cortices (PER), thalamus (THAL), mediodorsal thalamus (MDT),
somatosensory barrel field 1 (S1BF) and associative parietal cortex
(PtA), piriform cortex (PIR), amygdala (AMG), ventral tegmental
area (VTA) and substantia nigra (SN). Factors identified included
differences in whole structural sizes as well as changes in neuronal
density, size, shape, organization and localization. The second
goal of this work was to determine if reelin’s expression and
methylation levels as well as the number of reelin-positive cells are
affected in the hippocampal formation of MAM treated animals.
Reelin was selected for investigation due to its consistent
association with schizophrenia [23–27] and because it can affect
neuronal morphology, size and migration [49,50,51]. Moreover,
MAM’s mechanism of action could be related to its alkylating
effects over the reelin gene.
Methods
Animals
Thirty pregnant Sprague-Dawley dams (Charles River, France)
were obtained at embryonic day 10 and housed individually. On
E17, the dams were treated with methylazoxymethanol 25mg/kg
(Midwest Research Institute, Kansas City, MO, USA) or saline
solution intraperitoneally (i.p., 1ml/kg). MAM and sham litters
were grouped respectively. Rats born from saline-injected
pregnant rats served as controls. Pups were weaned twenty-one
days after birth and placed into cages suitable for two or three
animals. Rats were kept on a 12-hour light/dark cycle and
received water and food ad libitum before being sacrificed as adults
for immunohistochemistry. A second batch of eleven pregnant
Sprague-Dawley animals treated identically was later used to study
reelin methylation and expression levels in the hippocampus. All
experiments had the local Ethics Committee agreement num-
ber P2.TJ.104.09 (Comite ´ regional d’e ´thique pour l’expe ´rimenta-
tion animale, Ile-de-France – Rene ´ Descartes) and were performed
following the French Agriculture and Forestry Ministry regulations
(decree 874848, license A91429) which are in accordance with the
European Union guidelines concerning the care and use of
laboratory animals.
Brain removal and storage
At six months of age, 26 rats (13 males and 13 females) from the
first batch and 14 female rats from the second batch were
sacrificed via CO2 inhalation and their brains were removed from
their skulls. For the first batch of animals, brains were fixed in
formol-Zn at 4uC for 24 hours. Before the embedding cycle, which
consists of increasing alcohol baths for tissue dehydration, toluene
was used as a solvent and finally paraffin was applied. For the
second batch of 11 animals the hippocampus was dissected and the
procedures described in the reelin methylation and expression
sections were followed.
Stainings and immunohistochemistry
Paraffin-embedded brains from 14 control and 12 MAM-
exposed animals were cut in 5 mm slices with a microtome Microm
HM340E and fixed on Superfrost Plus slides (Menzel-Gla ¨ser) in
parallel series. From the 14 control brains and the 12 MAM-
exposed brains, 9 (5 males and 4 females) from each group were
included in the analyses. The remaining brains were not suitable
for analysis due to technical difficulties. Two levels were chosen
involving the hippocampus; Bregma 23.4 to 23.8 mm and
Bregma 25.3 to 25.7 mm. 60 slices were made for each level and
3 to 5 sections were studied per level. After an overnight passage in
the drying oven, slices were conserved at 4uC. Brain slices’
adhesion to glass slides was improved by a two minutes passage in
the microwave oven.
Immunolabelling was performed using a protocol based on the
avidin-biotin-peroxidase system based on the Vectastain ABC kit
(Vector Laboratories). Endogenous peroxidase activity was
quenched by incubating the brain slices for 15 minutes in 0.3%
hydrogen peroxide. Antigenic sites were revealed by a microwave
cycle in a citrate buffer. Slides were then mounted on cover slips
and incubated with anti-NeuN (Neuronal Nuclei, 1:500), anti-
GFAP (GlioFibrilar Acid Protein, 1:200) or anti-reelin (1:1000)
antibodies for an hour at room temperature. Then, sections were
incubated in avidin-biotin complex (Vectastain ABC kit, Vector
Laboratories) for 30 minutes and 3,39-diaminobenzidine (Dako-
cytomation) was used as a chromogen. Slices were washed with
distillate water, counterstained with hematoxylin, dehydrated with
alcohol and mounted in Merckoglass medium (Merck).
Morphometric Analysis
Microscopy. Our preparations were analyzed on a Nikon eclipse
E600 type 120 light microscope at magnifications of 206.
Quantifications at 1006, 2006 and 4006 and the numerical
acquisition of images were performed on a Nomarsky Zeiss
Axioplan brightfield microscope and a Nikon Dig Cam DXM1200
connected to a PC unit. Thickness and area measurements. Area
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ERC and the lateral ventricles as well as thickness for the S1BF,
PtA, ERC, PER, and PIR cortices were identified using anatomic
positions relative to cerebral structures described by The Rat
Brain Atlas [52]. Heterotopias and discontinuities. Heterotopias,
defined as a group of misplaced neurons, were counted in the
hippocampus from MAM and control animals. Discontinuities
were defined as a disruption in the Cornu Ammonis (CA) layers
characterized by the presence of an interruption in the neuronal
layer continuity and dispersed neurons on any side of the cellular
layer. Neuronal density assessments. Neuronal density was calculated as
the number of neurons divided by the area (mm
2) of interest. At
Bregma 23.6 to 23.8 mm neuronal density was determined in
the S1BF, MDT, PER, ERC, CA1, CA2, CA3, CA4 and DG.
Note that CA4 corresponds to the polymorphic layer of the
dentate gyrus [53]. This substitution was made to facilitate the
comparison with postmortem brains from patients with schizo-
phrenia. Area, thickness and neuronal number quantification. Area,
thickness and neuronal number measurements were made with
the image analysis software Lucia G (Nikon, France). At least 8 rats
were used for each group and at least four mean measurements
(n=4–6) for each animal were used to analyze inter-group
variations. Neuronal size measurement. Sections stained with antibod-
ies against the neuronal marker Neu-N were used for neuronal size
measurements. Neuronal size in the ENT, S1BF and MDT was
determined with an algorithm from the image analysis software
Metamorph (Metamorph, Molecular Devices, France). First,
pictures were calibrated according to the objective used in the
microscope. Second, we used the Metamorph morphology filter to
obtain the background in white (parameter ‘Suppress dark
objects’) and the objects in black (parameter ‘Border objects’).
This filter permits the software to accurately discriminate objects
from background. Then, an ‘inclusive threshold’ was adjusted so
as to select the entire body of neurons. The background noise was
eliminated by defining the minimum number of pixels necessary to
consider them as an object (parameter ‘Pixel area’ arbitrarily
defined as 200). In addition, neurons were identified by
Metamorph through shape (‘shape factor’ arbitrarily defined as
0.2) and length (‘Length’ defined as .10mm). These settings were
validated through the comparison between manual neuronal
counts in the original picture, manual neuronal counts in the
‘thresholded’ picture and the result of neuronal counts provided by
Metamorph. No difference was seen between these different
procedures. Finally, the Metamorph tool ‘Integrated morphome-
try analysis’ was used to calculate the neuronal soma area selected
by the algorithm. Neuronal density in hippocampal layers did not
allow the individualization of neurons. Cross-sectional areas of
neuronal somas were thus measured manually in CA1, CA2, CA3,
CA4 and DG.
Methylation
Hippocampal Deoxyribonucleic acid (DNA) from the second
batch of 11 rats was treated with sodium bisulfite using the
EpiTect Kit H (Epigenomics, Qiagen, BBBB). Three brains from
this batch of animals were not suitable for analysis due to technical
difficulties. Briefly, 1mg of DNA in a volume of 20ml was mixed
with 35ml of DNA Protect Buffer and 85ml of Bisulfite Mix.
Bisulfite conversion was achieved using 3 cycles of denaturation
(5 minutes at 99uC) and incubation (25, 85, and 175 min
respectively at 99uC). Modified DNA was purified by EpiTect H
spin columns and used immediately or stored at 220uC. Bisulfite-
modified genomic DNA was amplified with primers specific for
the reelin promoter (59-CGTTTTTTTATTTTGGTTTGGT-39
(forward), and 59-TCATATCATACATAACCACTATCCCTA-
39 (reverse). The polymerase chain reaction (PCR) conditions were
95uC for 15 minutes, 5 cycles of 95uC for 30 s, 56uC for 90 s,
72uC for 120 s, 25 cycles of 95uC for 30 s, 56uC for 90 s, 72uC for
90 s, and finally 7 minutes at 72uC. The PCR mixture contained
12.5ml of HotStarTaq Mix (Qiagen), 0.5ml of each primer at a
20mM concentration, and 2ml bisulfite modified DNA. These first-
round PCR products were then used as template (1ml) and
reamplified by tagged primers (59-CCACTCACTCACC-
CACCC+forward primer-39 and 59-GGGTGGGAGGTGG-
GAGGG+reverse primer-39). The second-round PCR conditions
were 95uC for 15 min, 35 cycles of 95uC for 30 s, 55uC for 90 s,
65uC for 120 s, and finally 7 min at 65uC. PCR products were
then purified with a Gel Extraction Kit (Qiagen) and subjected to
direct cycle sequencing on an ABI3100Avant automated DNA
sequencer (Applied Biosystems, Foster City, CA, USA), using the
primers from the 2
nd round of PCR. Sequence chromatographs
were analyzed by the software ESMEH (Epigenomics), which
performs quality control, normalizes signals, corrects for incom-
plete bisulfite conversion, and maps positions in the trace file to
CpG in the reference sequence.
Expression
Total Ribonucleic acid (RNA) from hippocampal samples from
the second batch of 11 animals was extracted and prepared by
RNeasy mini Kit (Qiagen), according to the manufacturer’s
protocol. Reverse transcription was performed by using the
Superscript II First Strand DNA synthesis system (Invitrogen).
Quantitative PCR was performed using SYBR Green I Master
Mix Buffer (Applied Biosystems, Foster City, CA, USA), and
reactions were run on a SDS7000 (Applied Biosystems, Foster
City, CA, USA) using a three-step standard protocol. b-actin was
used as an internal standard, and DCT values were calculated
from differences between the analyzed genes and b-actin. The
following primer pairs were used: CTGCTGGACTTCTC-
TACGGAT (forward), CAGTAGAGGTGGAAGGATGGG
(reverse).
Statistics
Data were analyzed using one-way ANOVAs with prenatal
treatment as a between-subjects factor (sham vs. MAM), except for
the number of heterotopias and discontinuities that were analyzed
using the Mann-Whitney U test of rank. Methylation levels were
compared by a two-way ANOVA analysis (CpG site and group as
factors). For global methylation and reelin expression levels, the
two groups were compared using the Mann-Whitney non
parametric test. Level for significance was set at p,0.05.
Results
The methodology followed was mostly determined by the fact
that considerable amounts of data coming from postmortem
brains of patients with schizophrenia are performed via two-
dimensional (2D) techniques (Tables 1 and 2). In addition, both
methods, two-dimensional as well as three-dimensional carry their
own flaws [54] and if these confounders are not taken into account
significant biases emerge [55,56]. As will be discussed in the later
sections of this manuscript, particular attention was paid to avoid
as much as possible potential artifacts that could mislead our
results.
Morphometric effects of MAM E17 treatment on brain
structures
The general appearance of MAM-exposed brains did not differ
from that of control animals, although MAM-exposed brains
Rats Exposed to MAM
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istic was confirmed after measuring brain area and circumference
at Bregma 23.6mm (Figure 1A) as both analyses rendered
statistically significant diminutions (Figure 1B and C) (p,0.001
and p,0.01 respectively). In addition, there was a reduction in the
cortical volume that was more pronounced in the posterior cortex
where the subcortical colliculi becomes exposed.
Subsequently, we sought morphometric changes at Bregma
23.6mm and Bregma 25.8mm levels through combined Nissl
and luxol staining (Kluver-Barrera technique), which highlights
myelin, fibre bundles and cell nuclei. Area and thickness of the
anatomical structures studied were measured as shown on
Figure 1A. At Bregma 23.6mm, MAM-exposed brain areas were
significantly reduced in the HIP (p,0.01), DG (p,0.001), THAL
(p,0.05), MDT (p,0.05) and ERC (p,0.05) (Figure 1D).
Likewise, the thickness of the ERC, PER and S1BF cortices was
significantly decreased (p,0.05, p,0.05 and p,0.01 respectively)
when compared to controls (Figure 1F). In contrast, neither the
AMG, PtA nor PIR cortex showed any differences in area or in
thickness at this level (Figures 1D and F). Bregma 25.8mm level
analysis also revealed a significant decrease in the hippocampal
area (p,0.05) and a tendency towards a significantly smaller DG
(p=0.07) (Figure 1E). The other structures studied, including the
AMG, ERC and VTA did not show any changes at Bregma
25.8mm (Figure 1E). ERC and PER thickness at the same level
also did not reveal any differences (Figure 1G).
Table 1. Neuronal size and density in the hippocampal formation of MAM-treated rats and patients with schizophrenia.
Anatomical area
in MAM
1-treated rats Findings
Comparable studies
in schizophrenia Anatomical Area Findings
Hippocampal
subfields
2CA1 and CA4
Unchanged neuronal
density by 2D
3 methods
Falkai and Bogerts,
1986
CA1 and CA4 Decreased neuronal density by 2D methods
Jeste and Lohr, 1989 CA1 and CA4 Decreased neuronal density by 2D methods
Heckers et al, 1991 CA1 and CA4 Unchanged neuronal density by 3D
4 methods
Benes et al, 1991 CA1 Decreased neuronal density by 2D methods
Arnold et al, 1995 CA1 and CA4 Unchanged neuronal density by 2D methods
Zaidel et al, 1997a CA1 (right) Increased neuronal density by 2D methods
Benes et al, 1991 CA4 Unchanged neuronal density by 2D methods
Zaidel et al, 1997a CA4 Unchanged neuronal density by 2D methods
Walker et al, 2002 CA1 and CA4 Unchanged neuronal density by 3D methods
Schmitt et al, 2009 CA1 and CA4 Unchanged neuronal density by 3D methods
Hippocampal subfield
CA2
Decreased neuronal
density by 2D methods
Falkai and Bogerts,
1986
CA2 Decreased neuronal density by 2D methods
Jeste and Lohr, 1989 CA2 Decreased neuronal density by 2D methods
Heckers et al, 1991 CA2 Unchanged neuronal density by 3D methods
Benes et al, 1991 CA2 Unchanged neuronal density by 2D methods
Arnold et al, 1995 CA2 Unchanged neuronal density by 2D methods
Walker et al, 2002 CA2 Unchanged neuronal density by 3D methods
Schmitt et al, 2009 CA2 Unchanged neuronal density by 3D methods
Hippocampal
subfield CA3
Increased neuronal
density by 2D methods
Falkai and Bogerts,
1986
CA3 Decreased neuronal density by 2D methods
Jeste and Lohr, 1989 CA3 Decreased neuronal density by 2D methods
Heckers et al, 1991 CA3 Unchanged neuronal density by 3D methods
Benes et al, 1991 CA3 Unchanged neuronal density by 2D methods
Arnold et al, 1995 CA3 Unchanged neuronal density by 2D methods
Zaidel et al, 1997a CA3 (right) Increased neuronal density by 2D methods
Walker et al, 2002 CA3 Unchanged neuronal density by 3D methods
Schmitt et al, 2009 CA3 Unchanged neuronal density by 3D methods
Hippocampal subfields
CA3 and CA4
Decreased neuronal
soma size by 2D methods
Benes et al, 1991 All CA subfields Decreased neuronal soma size by 2D methods
Arnold et al, 1995 All CA subfields Decreased neuronal soma size
(but only significant for CA1) by 2D methods
Zaidel et al, 1997b All CA subfields Decreased neuronal soma size by 2D methods
Jonsson et al, 1999 All CA subfields Decreased neuronal soma size by 2D methods
Highley et al, 2003 All CA subfields Unchanged neuronal soma size by 3D methods
1Methylazoxymethanol during embryonic day 17.
2Cornu ammonis.
3Two dimensional.
4Three dimensional.
doi:10.1371/journal.pone.0010291.t001
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after MAM E17 treatment
The neuronal density and neuronal soma size were examined in
all the anatomical structures revealing decreased area or thickness
in MAM-treated rats. However, the neuronal cytoarchitecture was
only studied in the hippocampal formation (ERC plus all the
hippocampal subfields) because it is in this brain region where
cytoarchitectural anomalies have been reported in schizophrenia
[57] and because this is the targeted brain region at E17.
In order to assess neuronal organization, density, size and
morphology in the entorhinal cortex, two staining methods were
used (Figures 2A and B). One method was Bodian-Luxol, which
highlights myelin and neuronal soma (Figure 2A). The other
marker utilized was through anti-NeuN antibodies that bind
specifically to the DNA-binding protein NeuN (Figure 2B). This
protein is specific for neurons and is restricted to the axon hillock,
the neuronal soma and the nucleus. These staining methods
evidenced well defined layers in the entorhinal cortex of control
animals where somas had a columnar organization and axon
hillocks had parallel directions (Figures 2 C, D and E). In contrast,
in MAM-exposed brains, cellular organization in this same
anatomical area was less strict and axons with perpendicular
orientation could be seen (Figures 2 F, G and H). In addition,
columns were less obvious and neuronal clusters were present. In
some animals, large isolated neurons could be identified (Figures 2
C, D and E). Neuronal clusters were mostly found in layers II and
III of the ERC of MAM-treated rats (Figures 2 C, D and E).
Discontinuities and heterotopias in the dorsal hippocampus
were also quantified using NeuN immunostaining (Figure 3).
MAM-exposed rats exhibited more discontinuities in CA1
(p,0.001), CA2 (p,0.001), and CA3 (p,0.05) (Figures 3A and
B). The number of heterotopias present in the dorsal hippocampus
was also more common in MAM rats (p,0.05) (Figures 3C and
D). Moreover, the neuronal density was significantly decreased in
CA2 (p,0.01) whereas the opposite was observed in CA3
(p,0.05) of exposed animals (Figures 4A and C). No differences
in the neuronal density were observed in subfields CA1, CA4 or
DG (Figure 4C). Likewise, no differences in neuronal soma size
were found in CA1, CA2 or DG whereas significant reductions
were encountered in CA3 and CA4 (both p,0.01) (Figure 4E).
The neuronal density did not differ between MAM and control
rats in the MDT, S1BF, ERC or PER (Figure 4B). On the other
hand, the neuronal soma size was significantly decreased in the
MDT, S1BF, ERC and PER (all p,0.05 except PER p,0.01)
(Figure 4D).
Ventricular enlargement induced by MAM E17 treatment
An obvious enlargement of the lateral ventricles could be seen in
several MAM rats. Nonetheless, this effect was not statistically
significant likely due to its not systematic presence (p.0.05)
(Figure 5). To verify that the ventricle enlargement was not due to
a freezing artefact, the integrity of the ventricular epithelium was
analyzed. Anti-GFAP immuno-staining was performed in order to
reveal tanycytes, which are specialized astrocytes localized at the
border of ventricles (Figure 5). The presence of these cells is
consistent with an intact ventricular epithelium. The subpial layer
is easily distinguishable, vascular and lepto-meningeal endings of
astrocytes highlight the presence of blood vessels and delineate
brain tissue borders. Tanycytes were well differentiated from
protoplasmic astrocytes through their stellar arborizations. In
MAM rats, the presence of tanycytes bordering the ventricles
confirmed that the ventricular enlargement observed was
effectively due to atrophy of underlying structures and not to a
freezing artefact. Therefore, ventricular enlargement was a
consequence of MAM exposure but as mentioned above its
inconsistent presence rendered it non-significant (Figure 5).
Hippocampal quantification of reelin expression,
methylation and reelin containing cells
Reelin containing cells were assessed in the hippocampus at
Bregma 23.8mm level (Figure 6A). There were no differences in
the number of reelin positive cells between MAM and control
animals (Figure 6B). Since the number of reelin-containing cells
does not exclude a potential deficit in reelin’s expression or
methylation a different batch of MAM and control animals was
used to pursue these assessments.
The amplification of a 252 bp sequence located in the reelin
promoter allowed the determination of the methylation level of
five CpGs situated at 2782, 2772, 2768, 2754, and 2750 from
the first base of exon 1. ANOVA analysis embracing the CpG site
and group as factors revealed only a tendency towards
hypermethylation of the reelin promoter in MAM-treated rats (F
(1,74)=3.2, p=0.075) (Figure 6C). However, global methylation
levels computed through means of the median of the five CpG sites
Table 2. Neuronal size and density in the entorhinal cortex of MAM-treated rats and patients with schizophrenia.
Anatomical area
in MAM
1-treated rats Findings
Comparable studies
in schizophrenia
Anatomical
Area Findings
ERC
2 Unchanged neuronal
density by 2D
3 methods
Falaki et al, 1988 ERC Decreased neuronal density by 2D
methods
Arnold et al, 1995 ERC Unchanged neuronal density by 2D
methods
Krimer et al, 1997 ERC Unchanged neuronal density by 2D
methods
ERC Decreased neuronal
soma size by 2D methods
Jakob and Beckmann,
1994
ERC Decreased neuronal soma size
(qualitative)*
Arnold et al, 1995 ERC Decreased neuronal soma size by 2D
methods
1Methylazoxymethanol during embryonic day 17.
2Entorhinal cortex.
3Two dimensional.
*All other studies were quantitative.
doi:10.1371/journal.pone.0010291.t002
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PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10291Figure 1. Morphometric effects of MAM E17 treatment on brain structures. (A) Brain diagrams reproduced with permission from The Rat
Brain Atlas by Paxinos and Watson 6 edition illustrating how anatomical areas were delineated. Bregma 23.8mm on left and Bregma 25.8mm on
right. Areas and thicknesses were measured as delineated in the pictures. (B–C) Graphs indicating differences in brain area (B) and circumference (C)
between control (white bars) and MAM-exposed animals (black bars). (D–E) Graphs indicating area differences between MAM and control animals at
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Whitney=9, p=0.34). Moreover, reelin expression levels did
not change between MAM and control animals (U-Mann
Whitney=25, p=0.81) (Figure 6D).
Discussion
Methodological Considerations
Within the neuroscientific community it is commonly believed
that three-dimensional (3D) assessments provide more accurate
results than 2D methods. However, both methodologies have their
own flaws [54] and when these artifacts are not considered
stereological 3D analyses could involve biases of up to 80% [55]
while the consideration of potential confounders leaves 2D
methods 2% short of brain section reconstructions [56]. One
confounder concerning stereological 3D methods involves brain
section shrinking that affects the edges more than the center of the
slice [54]. This non-linear distortion can directly alter the neuronal
density as well as the neuronal soma size [54], both of which
represent the focus of our analyses.
Two-dimensional techniques are by no means error-free. In
fact, the main confounder associated with the establishment of cell
numbers via 2D methodologies is cell over-counting. Biases are
introduced by counting soma cells more than once. This potential
artifact could be partially corrected by using the Abercrombie
equation [58] but irregularities in cell size and shape, as in the case
of the MAM model, limit the utility of such tool [59]. We did not
count any consecutive brain slices to avoid over-counting but we
did count at least 3 sections per level to reduce biases introduced
by potential changes in the shape of brain regions. As can be seen
in Figures 4B and C, the technique we followed gave quite
consistent results for neuronal numbers. The fact that we found a
decreased as well as an increased cell density in certain brain
regions of MAM-treated animals also indicates that there was not
an obvious over-counting of cells in either group. Moreover, these
density changes are in agreement with MAM effects as will be
discussed in the following sections. On the other hand, when the
neuronal soma size is under investigation, 2D methods have to rely
on finding the neuronal nucleolus to measure the main cell
circumference and avoid measuring an unevenly cut neuronal
body. The number of cells analyzed can also limit such a
confounder. It has been shown that lager sample sizes decrease the
likelihood of a biased result [60]. Consequently, we counted
between 400–500 cells per condition. Moreover, our results
concerning the neuronal soma size are again in line with MAM
properties as will be explained below. Additionally, a 2D approach
was used because the main goal of this work is to determine
if hippocampal formation size reductions found in schizophrenia
and the MAM model are caused by similar neuropathological
findings and most of the studies concerning this brain region
in affected individuals have been done via 2D methods
(Tables 1 and 2).
Neuropathological findings in MAM E17 rats and
schizophrenia; differences and similarities
Several features found in E17 MAM-exposed rat brains
resemble those described in the brains of patients with
schizophrenia, in particular the overall decrease in cortical size.
In schizophrenia, however, this cortical reduction is only evident
after meticulous analyses [61,62] whereas in MAM-treated
animals it is noticeable even through gross brain inspections
[63]. More specific examinations revealed size reductions in a
restricted number of brain regions as well as an obvious
enlargement of the lateral ventricles in several MAM rats but
ventricle enlargement, one of the most consistent findings in
schizophrenia [64,65], was not statistically significant in MAM-
exposed animals (Figure 5).
The subcortical area most commonly associated with schizo-
phrenia is the thalamus, in particular the MDT. Both structures
have consistently shown volumetric reductions in affected
individuals [66–70] albeit not always [71–73]. Likewise, the
MAM model evidences a smaller thalamus and has now replicated
data on MDT size reductions [45] (Figure 1D). Neuromorpho-
metric analyses indicate that the neuronal soma diminutions
reported by some authors in the MDT from patients with
schizophrenia [68] are also found in MAM-treated animals
(Figure 4A) (Table 3). When it comes to neuronal numbers in
this brain region, the literature is divided (Table 3). Five studies
have reported a decreased neuronal density in the MDT of
patients with schizophrenia [67,68,74–76] whereas four recent
reports, arguably following stricter methodologies, showed an
unchanged neuronal density in the MDT [66,71–73] (Table 3). In
MAM-exposed brains we found no changes in the neuronal
density in this thalamic nucleus (Figure 4B) but no hard
conclusions can be drawn regarding potential differences or
similarities with schizophrenia owing to discrepancies in the
literature concerning individuals with this psychotic illness
(Table 3).
The somatosensory cortex from MAM rats also evidences
smaller neuronal somas (Figure 4D), suggesting that dendrites and
axons are shorter [77–79] and consequently connectivity is
expected to be impoverished. These results are in line with
functional neuroimaging studies indicating that somatosensory
cortex activation is reduced in patients with schizophrenia [80,81].
Nonetheless, to our knowledge there are no neuroanatomical
reports from this cortical zone in schizophrenia and thus our
results in MAM rats will have to await correlation. The size of the
amygdala on the other hand, remains unchanged in MAM-
exposed animals (Figures 1D and E), which correlates with recent
postmortem and neuroimaging data from patients with schizo-
phrenia [17,82–84] although opposite results have also been
published [85].
Within the cortex, the largest body of evidence associates the
hippocampal formation, along with the dorsolateral-PFC, with
schizophrenia [41]. Neuropathological studies have contributed
considerably to this association. For instance, the dentate gyrus
from patients with this psychotic disorder has shown higher
numbers of granular cells with basal dendrites [86,87] but
potential deficiencies in its entire volume and its cytoarchitecture
are still to be determined. Therefore, our findings involving a size
reduction in the dentate gyrus (Figures 1D and E) do not strictly
parallel what is currently known in schizophrenia. More detailed
investigations embracing dendrite morphology in MAM-treated
rats are warranted. In contrast, the hippocampus and the
Bregma 23.6 (D) and 25.8mm (E). (F–G) Graphs indicating differences in thickness between MAM and control animals at Bregma 23.6 (F) and
25.8mm (G). Results represent the mean 6 S.E.M. of 9 animals per group from which slides done by duplicate were analyzed. Amygdala (AMG),
associative parietal cortex (PtA), cornu ammonis (CA), dentate gyrus (DG), entorhinal cortex (ERC), hippocampus (HIP), mediodorsal thalamic nucleus
(MDT), perirhinal cortex (PER), piriform cortex (PIR), somato-sensory cortex barrel field 1 (S1BF), substantia nigra (SN), thalamus (THAL), ventral
tegmental area (VTA). *p,0.05 **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0010291.g001
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PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10291Figure 2. Neuronal organization of entorhinal cortex in MAM and control rats. Coronal sections of the entorhinal cortex at Bregma
23.8mm from control animals stained with Bodian-Luxol (A) and NeuN immunostaining (B). (C) Bodian-Luxol staining of the entorhinal cortex from
control animals. A well defined columnar organization and myelin with parallel directions can be observed. Arrows point to myelin pathways. (D)
Anti-NeuN immunostaining of the entorhinal cortex from control animals showing axon hillocks with a parallel orientation and neuronal bodies
regularly organized. (E) Neuronal somas and axon hillocks are clearly distinguished in this picture magnified 4006. Arrows point to axon-hillock
direction. (F) Bodian-Luxol staining of the entorhinal cortex from MAM rats reveals a less obvious columnar organization while myelin direction
appears random. (G) NeuN immunostaining of the entorhinal cortex from MAM animals. Neuronal disorganization with clusters of neurons is evident
mainly in layers II and III. Circles highlight neuronal clusters. (H) Neuronal disorganization, neuronal size variability and axon hillocks with random
directions can be observed in this picture magnified 4006. Arrows point to axon-hillock direction.
doi:10.1371/journal.pone.0010291.g002
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10291Figure 3. Discontinuities and heterotopias in MAM and control animals. (A) Coronal slices at Bregma 23.8mm of the hippocampus, CA1,
CA2 and CA3 from MAM exposed rats stained with anti-NeuN antibody and 3,39-diaminobenzidine as chromogen. The rectangles in the first photo
indicate where the magnification shown in the three following photos comes from. Arrows point to actual discontinuities. (B) Graph bars indicating
discontinuity differences between MAM rats and control animals in hippocampal subfields CA1, CA2 and CA3. (C) Coronal slices at Bregma 23.8mm
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E and F), which corroborates previous findings from MAM
exposure at E17 [43,45] as well as earlier in embryonic life (E9–
E12) [30,31]. These results parallel the hippocampal and
perirhinal cortex volume loss consistently found in schizophrenia
[19,64,85,88–92] but in themselves these results are not specific.
Brain volume reductions could originate from a variety of causes
and only cytoarchitectural and neuromorphometric analyses could
establish if the MAM model does indeed replicate hippocampal
anomalies found in schizophrenia (Table 1). A more detailed
assessment revealed that the neuronal density is decreased in CA2,
increased in CA3 and unchanged in CA1 and CA4. Similar results
have been found in schizophrenia where CA2 density was
decreased [93,94], CA3 increased [95] and CA1 and CA4
unchanged [13,96–98]; however, other reports suggest that there
are no changes in CA2 and CA3 cell density [12,13,96–98] and
even that CA3 density is decreased [94]. Likewise, data on CA1 is
inconsistent, with some studies pointing to unchanged [12,96–98],
increased [95] and decreased density [13,94]. Thus, the reliability
of schizophrenia findings concerning hippocampal cell density is
limited making any comparisons dubious. More consistent findings
come from neuronal organization although controversy surround-
ing these results persists [41]. Neuronal disorientation has been
reported in several studies [99–102], albeit negative reports have
also been published [12–14,103]. In the MAM model, gross
inspection reveals a high degree of disorientation in hippocampal
neurons. But perhaps the most consistent finding in the
hippocampus of patients with schizophrenia concerns the neuronal
soma size (Table 1). Only one team has not found changes in the
hippocampal neuronal soma size [104], whereas three indepen-
dent groups have reported neuronal soma size reductions in all the
CA subfields of affected individuals [12–15]. MAM-treated rats
replicate such findings in hippocampal subfields CA3 and CA4
(Figure 4E).
The entorhinal cortex in psychotic individuals has shown whole
size reductions [11,18,19] along with laminar disorganization,
reduced neuronal soma size and the presence of neuronal clusters
[3,4,12,16]. All such findings are reproduced by the MAM E17
model to different extents (Table 2). Aberrantly clustered neurons
can be seen in layers II and III of MAM-treated animals
(Figure 2G). Layers II and III are also the most affected in
schizophrenia when it comes to abnormal neuronal clusters [3–6].
Layer disorganization in the ERC is also notably affected in both
entities [3,4] (Figure 2F). Additionally, heterotopias are present in
the entorhinal cortex of patients with schizophrenia [3,4,5],
whereas abnormally located neurons in the MAM model were
only seen in the hippocampus (Figures 3A, B, C and D). However,
all these findings could result from intrinsic anatomical variations
in the ERC [57]. In contrast, clear deficiencies were found by
assessing the neuronal density and the neuronal soma size
(Table 2). Neuronal density in the ERCs of affected individuals
has either been found to be decreased [18] or unchanged [9,12].
We found that neuronal density was unchanged in the ERC of
MAM-exposed rats (Figure 4B). The size of this brain region is
reduced in schizophrenia [11,17–19] and the neuronal soma is
diminished [12,16]. Likewise, in MAM-treated rats, entorhinal
cortex area and thickness were decreased (Figures 1D and F) and
this size reduction was associated with a significant neuronal soma
shrinkage (Figure 4D). Other teams have shown that MAM
exposure earlier in embryonic life (E9–E12) also causes ERC size
reductions at different bregma levels and that also compromises
the entorhinal cytoarchitecture [30–32]. Thus, a number of
neuropathological similarities within the hippocampal formation
can be found between MAM-exposed rats and patients with
schizophrenia. The possible physiological implications of these
neuropathological coincidences will be discussed in the following
sections.
MAM mechanisms of action and its implications for
cytoarchitecture, neuronal soma size and neuronal
density
MAM is mostly known as an antimitotic agent [36–38] while its
capacity to affect neurite outgrowth is less recognized [105,106].
However, it has been previously shown that dissociated hippo-
campal neurons from embryonic day 18 exposed to MAM are
unable to form axons or dendrites and that the few axons already
present retract [105]. Moreover, MAM significantly reduces
microtubule associated proteins (MAPs) 2 and 1B [105], two
proteins essential for neurite sprouting [107]. These results are
further supported by experiments in vivo in which the hippocampus
of animals treated with MAM at embryonic day 15 evidenced less
and shorter dendritic branches, abnormal dendritic shafts and
diminished spine numbers [106]. Our results, after MAM
exposure at embryonic day 17, appear to involve a combination
of both effects; that of an antimitotic agent and an inhibitor of
neurite formation. This is not surprising since at embryonic day 17
neurogenesis peaks in the hippocampal formation [39] and it is
also during this day when fibers interconnecting this brain region
are extended [40].
A closer look at each of the anatomical areas affected reveals
which mechanism was most influential. In the hippocampal
subfield CA2 an antimitotic effect appears to predominate since
the number of neurons decreased and there was no change in the
neuronal soma size (Figures 4C and E). All the other anatomical
regions affected exhibited deficits consistent with arrested neurite
formation as they presented decreased neuronal soma size and as
previously mentioned, neuronal soma size correlates with neuropil
length [77–79]. These anatomical regions include S1BF, MDT,
ERC, PER CA3 and CA4 (Figures 4D and E). CA3 is a particular
case because its neuronal density was also increased (Figure 4C). A
higher neuronal density coupled with a reduction in the
anatomical area size of, in this case, the hippocampus
(Figures 1E and F) indicates that the space between neurons is
reduced [108]. Since this space is usually occupied by dendrites
and axons, its reduction suggests that the neuropil is shrunken
[108]. Thus, CA3’s impoverished neuropil is supported by two
lines of information; neuronal density and neuronal soma size
(Figures 4C and E).
How MAM exerts its antimitotic and neurite outgrowth
inhibitory effects is still to be determined; one possibility is
through DNA methylation, a mechanism known to regulate gene
expression. MAM’s capacity to induce gene-methylation [36]
could affect reelin. Partial knockouts have shown that under-
expressing reelin during rodents’ development leads to neuronal
migration deficits [51] and to shorter hippocampal dendrites in
adulthood [49]. The phenotypic coincidences between partial
from MAM and control animals stained with anti-NeuN antibody and 3,39-diaminobenzidine as chromogen. The rectangles within the two left photos
indicate where the magnification shown in the two right photos comes from. The arrow points to an actual heterotopia. (D) Graph indicating number
of heterotopias in MAM rats’ hippocampus compared to control animals. Results represent the mean 6 S.E.M. of 9 animals per group from which
slides done by duplicate were analyzed. *p,0.05 and ***p,0.001.
doi:10.1371/journal.pone.0010291.g003
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PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e10291Figure 4. Neuronal density and neuronal soma size in MAM and control animals. (A) Coronal section at Bregma 23.8mm stained with anti-
NeuN antibody and 3,39-diaminobenzidine as chromogen indicating how hippocampal subfields were delineated. (B) Graph indicating changes in
neuronal densities from MDT, VPM, VPL, S1BF, PER and ERC between MAM (black bars) and control animals (white bars). (C) Graph indicating changes
in neuronal densities between MAM and control animals from hippocampal subfields CA1, CA2, CA3, CA4 and DG. (D) Graph indicating changes in
neuronal soma size from MDT, VPM, VPL, S1BF, PER and ERC between MAM and control animals. (E) Graph indicating differences between MAM and
control animals’ cross-sectional area of neuronal somas from CA1, CA2, CA3, CA4 and DG. Results represent the mean 6 S.E.M. of 9 animals per group
from which slides done by duplicate were analyzed. In graphs D and E individual values are the mean of at least 500 measured neurons for each
cerebral structure or hippocampal layer *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0010291.g004
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reelin might be implicated in MAM effects. In addition, reelin has
been consistently associated with schizophrenia where its expres-
sion and immunoreactivity were found to be decreased [23–25].
Besides, hypermethylation of the reelin promoter in patients with
schizophrenia has been reported [26,27]. Nonetheless, the most
recent study concerning reelin methylation in schizophrenia found
no differences with control individuals [29].
Our results indicate that reelin is not significantly affected in
MAM-treated rats. However, it has to be kept in mind that our
sample is rather small and that we measured reelin methylation
and expression in the entire hippocampus (Figures 6C and D).
Since neuropathological deficits were found in specific hippocam-
pal regions and not in the entire hippocampus a similar by region
analysis of reelin methylation and expression levels is warranted
before excluding reelin as a molecule involved in MAM’s
mechanism of action. It also has to be considered that MAM
could exert its effects by methylating other genes. A number of
genes involved in neurite outgrowth with replicated evidence of
their association with schizophrenia [109] could be potentially
involved in MAM’s neuropathological consequences. Further
research following these leads is being developed by our group
as we believe significant insight can be gained into the
pathophysiology of schizophrenia if abnormal neurite formation,
a proposed etiological factor for this illness [109], is factored into
the equation.
Plausible implications and future directions of MAM
neuropathological findings and its relation to
schizophrenia
The MAM model presents reductions in neuronal soma size
within the entorhinal cortex, CA3 and CA4 that resemble post-
mortem findings from schizophrenic patients (Table 1). These
soma size deficiencies suggest the dendritic arbor and the axonal
length are impoverished [77–79]. Consequently, efferents leaving
these anatomical structures are likely to be compromised. The
entorhinal cortex sends connections to the hippocampal forma-
tion [110] and to limbic structures [111] including the amygdala
[112] and the nucleus accumbens [113] while the hippocampal
subfields CA3 and CA4 only extend fibers within the hippocam-
pal formation [53]. Given that connections between the
entorhinal cortex and the hippocampus are an important
memory center, it is likely that the deficits encountered in the
hippocampal formation contribute to MAM rats’ cognitive
deficits [35,42,43]. This could be particularly true for visuo-
spatial anomalies as it was recently suggested that the entorhinal
cortex is the substrate for visuo-spatial representations [114].
Thus, it is not surprising that both entities, schizophrenia and
MAM-exposed animals, present neuropathological anomalies in
the entorhinal cortex (Table 2) as well as visuo-spatial deficiencies
[115–117]. The potential association between ERC anomalies
and visuo-spatial deficits is a research line to be followed up in
MAM-treated animals.
Figure 5. Ventricular size in MAM and control animals. (Top left) Coronal section from a representative MAM rat at Bregma 23.8mm stained
with anti-GFAP antibodies and 3,39-diaminobenzidine used as chromogen. An enlarged ventricle could be observed in the picture. (Top center and
top right) Three magnifications (106,2 6 and 26) are shown to evidence tanycytes, which are circled in the last magnification. (Bottom) Graph
indicating differences in ventricular size between MAM (black bars) and control animals (white bars). Results represent the mean 6 S.E.M. of 9 animals
per group from which slides done by duplicate were analyzed.
doi:10.1371/journal.pone.0010291.g005
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PLoS ONE | www.plosone.org 12 April 2010 | Volume 5 | Issue 4 | e10291Figure 6. Reelin-containing cells, reelin expression and methylation in the hippocampus of MAM and control animals. (A) Coronal
slices from MAM and control animals at Bregma 23.8mm stained with anti-reelin antibodies and 3,39-diaminobenzidine used as chromogen. (B)
Graph indicating differences in reelin positive cells between MAM (black bar) and control animals (white bar). Results represent the mean 6 S.E.M. of
9 animals per group from which slides done by duplicate were analyzed. (C) Graph bars indicating methylation differences between MAM and control
animals in five CpGs (2782, 2772, 2768, 2754, and 2750) from the reelin promoter within the hippocampus. Methylation levels are expressed in
percentage for Sham and MAM groups by each measured CpG site. (D) Graph bars indicating differences in reelin mRNA expression from MAM and
control rats’ hippocampus. Reelin mRNA expression levels were plotted as delta CT values.
doi:10.1371/journal.pone.0010291.g006
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exposed animals and patients with schizophrenia comes from the
potential decline of efferents leaving the entorhinal cortex to reach
the hippocampal subfields including the dentate gyrus [110].
These fibers are essentially glutamatergic [118] and thus their
shrinkage in the E17 MAM model, suggested by a reduction in the
neuronal soma size (Figure 4D), would be in line with the
hypoglutamatergic hypothesis of schizophrenia. Nonetheless,
evidence of direct glutamatergic deficits in the MAM E17 model
is still lacking.
Also relevant to schizophrenia is the infraconnectivity between
the entorhinal cortex and limbic structures [111–113] presumably
present in MAM rats (Figure 5A). In humans, impaired limbic
connectivity is thought to be implicated in the negative symptoms
observed in schizophrenia. MAM-treated rats show behaviors that
parallel negative symptoms such as deficits in social interaction
[42,43]. Thus the MAM model provides the opportunity to further
investigate a potential association between deficient ERC
projections to limbic structures and social interaction anomalies.
In conclusion, we can say that even though not all the
neuropathological findings encountered in patients with schizo-
phrenia are replicated by the MAM E17 model and vice versa,
the findings presented here indicate that there are significant
similarities in the hippocampal formation of both conditions. Of
note, these deficits point to abnormal neurite formation, a
recently proposed etiological factor for schizophrenia [109].
Finally, our results along with their implications in cognition and
behavior provide further support for the MAM E17 model as a
useful tool for studying the pathophysiology of this psychotic
disorder.
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